Capmatinib

Drug Profile

Capmatinib

Alternative Names: INC-280; INCB-028060; INCB-28060

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma; Hepatocellular carcinoma; Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Head and neck cancer
  • Phase I Renal cell carcinoma; Solid tumours

Most Recent Events

  • 09 Aug 2017 Novartis plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) (NCT03240393)
  • 24 Jul 2017 Novartis Pharmaceuticals terminates a phase I/II trial in Head and neck cancer and Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, Canada, Spain, France, Germany, Italy and Belgium, because of difficulties in identifying patients who met the eligibility criteria (NCT02205398)
  • 04 Jul 2017 Novartis completes a phase I trial in Solid tumours (Late-stage disease) in USA, Australia, Canada, France, Germany, Hong Kong, Israel, Italy, South Korea, Netherlands, Norway, Singapore, Spain, Thailand and Taiwan (PO) (NCT01324479)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top